Kardigan raises $400M in IPO to back three clinical-stage cardio drugs

Tassos Gianakakos, Kardigan CEO June 17, 2026 08:48 PM EDTUpdated 09:18 PM IPOs Kardi­gan rais­es $400M in IPO to back three clin­i­cal-stage car­dio drugs Kyle LaHucik Biotech Correspondent More ev­i­dence has ar­rived that biotech IPOs are alive and well: A car­di­ol­o­gy drug de­vel­op­er with three clin­i­cal-stage can­di­dates just se­cured $400 mil­lion for its … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER